Deutsche Bank Maintains Buy on Keysight Technologies, Lowers Price Target to $190

Deutsche Bank analyst Matthew Niknam maintains Keysight Technologies (NYSE:KEYS) with a Buy and lowers the price target from $193 to $190.

byBenzinga Newsdesk

November 18, 2022

1 minute read

Deutsche Bank analyst Matthew Niknam maintains Keysight Technologies (NYSE:KEYS) with a Buy and lowers the price target from $193 to $190.

Barrington Hikes ICF Price Target By ~3%

By Akanksha Bakshi

Today, 8:44 AM

Barrington analyst Kevin Steinke raised the price target on ICF International Inc (NASDAQ:ICFI) to $121 from $118 while maintaining the Outperform rating on…

ICFI

Raymond James Maintains Market Outperform on XPO Logistics, Raises Price Target to $102

By Benzinga Newsdesk

Today, 8:44 AM

Raymond James analyst Patrick Tyler Brown maintains XPO Logistics (NYSE:XPO) with a Market Outperform and raises the price target from $100 to $102.

XPO

9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19

By Benzinga Newsdesk

Today, 8:44 AM

9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today

NMTR

WESCO Clocks 17% Revenue Growth In Q4, Tops Street View

By Akanksha Bakshi

Today, 8:44 AM

WESCO International, Inc. (NYSE:WCC) reported fourth-quarter sales growth of 17.5% year-over-year to $4.85 billion, +15.8% on an organic basis, beating the…

WCC

Deutsche Bank Maintains Buy on Keysight Technologies, Lowers Price Target to $190

Related Posts

Barrington Hikes ICF Price Target By ~3%

Raymond James Maintains Market Outperform on XPO Logistics, Raises Price Target to $102

9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19

WESCO Clocks 17% Revenue Growth In Q4, Tops Street View